Follow the Pundits
Tag: long term investing
🏛️ The Abrams Capital Matrix: How David Abrams Turned a 40% Bet Into a $10 Billion Value Fortress
Most hedge funds diversify. David Abrams does the opposite. The former Baupost analyst has built a $10 billion investing fortress around patience, concentration, and a stunning 40% position in aerospace supplier Loar Holdings. Here's what investors can learn from one of Wall Street's quietest billionaires.
Baillie Gifford Review 2026: The Long-Term Kings of Disruptive Growth 🏴☠️
Baillie Gifford invests like a time traveler—betting on companies that could dominate the next decade. But with great upside comes serious volatility. Here’s the full 2026 breakdown.
Baillie Gifford (BGKEX): 40% Returns, 7-Year Bets — Is This the Ultimate EM Growth Fund? 🌏
A 40% year, a 7-year mindset, and a bold bet on global growth—Baillie Gifford’s Emerging Markets fund might be one of the most interesting long-term plays today.
UNP Stock Analysis 2026: Is Union Pacific a “Core Compounder” or Just Fully Priced?
Union Pacific (NYSE: UNP) is the institutional-grade backbone of American freight. With elite operating efficiency, steady dividend growth, and near-ATH pricing, the question isn’t whether it’s good — it’s whether you’re paying too much for quality.
Madrigal, BeiGene, and Biotech Alpha: Inside the “Gene-ius” Kingmakers of Baker Bros. 2025
Biotech Jedi at work. Baker Bros’ 2025 victory lap shows how Madrigal, BeiGene, and ruthless conviction turned science into serious alpha.
Berkshire Hathaway's 2025 Scorecard: Defensive Portfolio, Slightly Underwhelming Performance — But a Historic Transition
Berkshire played defense in 2025: record cash, cautious positioning, and the end of an era as Warren Buffett stepped aside. Solid, sober, and very Berkshire.
John Rogers’ Ariel Investments Loves Madison Square Garden Entertainment: Should You?
MSGE owns some of the world’s most iconic entertainment venues. Demand is strong — but leverage and price argue for patience.
Nvidia Is a Top-Five Stock Held by Hedge Funds: Should You Buy — or Even Hold?
Nvidia is the crown jewel of AI and a top hedge-fund holding. The company is stellar — but is the stock still worth buying in 2026?
Hedge Funds Like Royalty Pharma: Should Retail Wear the Crown?
Royalty Pharma isn’t a biotech moonshot — it’s a cash-collecting royalty king. Hedge funds are buying, buybacks are flowing, and dividends keep compounding. 👑💊
Buffett Steps Down as CEO — Should You Step Away from Berkshire?
Buffett steps aside as CEO. The cash pile is massive. The machine still hums. Should long-term investors stay the course with Berkshire Hathaway?